The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial
Constantine S. Tam(The Alfred Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Carmen DiCorleto(Monash Health), Eric Hedrick(Florida Hospital Cancer Institute), Michael Gilbertson(Monash Health), Matthew Ku(St Vincent's Hospital Melbourne), John F. Seymour(The Royal Melbourne Hospital), Stephen Opat(Monash Health), Mary Ann Anderson(The Royal Melbourne Hospital), Andrew Grigg(The Royal Melbourne Hospital), Lusong Luo(Beijing Biocytogen (China)), Ling Xue(Jilin University), Belinda Dimovski(Peter MacCallum Cancer Centre), Lai Wang(BeiGene (China)), Jianxin Yang(BeiGene (China))
Cited by 111
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k